Notal Vision Awarded 2013 Arch Grant

Share Article

Ophthalmic medical device company named one of this year's winners of the Arch Grants Business Plan Competition.

We are pleased to be awarded an Arch Grant. St. Louis offers great advantages for our Israeli company as we look to expand our presence in the U.S. market.

Notal Vision™ has been named one of the 2013 winners of the Arch Grants Business Plan Competition. Out of 707 applicants from 15 countries and 40 states, Notal Vision will be one of 20 winners to receive $50,000 in funding and access to free support services.

The Arch Grant will help Notal Vision introduce their ForeseeHome™ AMD Monitoring Program nationwide. The ForeseeHome is the first FDA-cleared telemonitoring system for patients with age-related macular degeneration (AMD) and allows physicians to detect and treat the disease early.

“We are honored to be one of the Arch Grant award winners,” says U.S. General Manager, Garrett O’Connell. “As an Israeli company focused on growth in the U.S. market, we chose St. Louis for our U.S. headquarters. The central location and reasonable cost of living are just a couple of the benefits of St. Louis and we’re excited to be part of the growing community of medical and biotech start-ups here.”    

Notal Vision Co-Founder and CEO, Dr. Barak Azmon, added, “We are pleased to be awarded an Arch Grant. St. Louis offers great advantages for our Israeli company as we look to expand our presence in the U.S. market.”

The National Eye Institute (NEI), a division of the U.S. National Institutes of Health, is conducting a clinical trial with the ForeseeHome designed to compare the benefit of home based telemonitoring for AMD versus the current standard of care (no telemonitoring). Results from this trial are expected to be announced later in 2013.

Notal Vision is preparing for commercial launch of the ForeseeHome in late 2013.

About the ForeseeHome™ AMD Monitoring Program

The ForeseeHome AMD Monitor is the first FDA-cleared home-based telemonitoring system for patients with age-related macular degeneration (AMD). It is indicated for patients diagnosed with the dry form of AMD who are at risk of developing the sight threatening wet form of AMD. The ForeseeHome utilizes a proprietary technology platform called Preferential Hyperacuity Perimetry.

Patients complete a short test on their ForeseeHome system from the comfort of their home. These test results are automatically transmitted to the Notal Vision Data Monitoring Center through an imbedded cellular or phone modem and are available to the prescribing doctor and patient through a secure website. If there is a statistically significant change in test results, Notal Vision will promptly alert the doctor and the patient so that a comprehensive eye exam can be scheduled.

Due to the rapid progression of vision loss associated with wet AMD, ForeseeHome testing is recommended daily. Early detection and early treatment of wet AMD are the best chance to prevent vision loss and preserve quality of life.

About Notal Vision™

Notal Vision develops and markets innovative ophthalmic technology designed to facilitate early disease intervention by physicians resulting in the best possible visual outcomes for patients. Notal Vision was founded by two ophthalmologists determined to reduce vision loss and blindness associated with age-related macular degeneration, the leading cause of severe vision loss in the elderly population in the western world. A pioneer in the ophthalmic industry, Notal Vision maintains corporate headquarters in Tel Aviv, Israel and U.S. headquarters in St. Louis, MO.

For additional information about Notal Vision or the ForeseeHome AMD Monitoring Program, visit http://www.foreseehome.com.

Contact:

Jodi Wiener            
Marketing Coordinator        
Notal Vision
2319 Weldon Parkway
St. Louis, MO 63146
877-322-2207
jodi(at)notalvision(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jodi Wiener
Notal Vision
877-322-2207
Email >
Visit website